Tag Archives: The Tufts Center for the Study of Drug Development

CAR-T Therapy: Personalized medicine with the promise of a cure; payers will decide who gets it






The News: Swiss drug giant Novartis AG has drawn widespread praise and a rising dose of controversy pertaining to its breakthrough CAR-T therapy CTL019. The medicine is under review to… Read more »

China’s FDA approves AstraZeneca’s lung-cancer drug in new “fast-track” program; European drugmakers beating US to world’s biggest drug market






The News: AstraZeneca PLC (London) has won approval for its lung-cancer pill Tagrisso in China, a key market for the potential blockbuster medicine. Tagrisso is designed to help cancer patients… Read more »

Marathon’s defense of pricey orphan drug getting spotlight in Congress; running a marathon is far easier, and a lot cheaper






Steve’s Take: Marathon Pharmaceuticals LLC (Northbrook IL) caught my attention last month at the inception of an outcry when the company first announced the $89,000 price tag for its newly… Read more »

GE Healthcare Barges into Cell-Therapy Arena with Swiss Buy; Where’s the FDA?






GE Healthcare (Little Chalfont GBR) just signaled its intention to build a $1 billion business which offers specialized manufacturing tools for an upcoming tidal wave of cell therapies by acquiring… Read more »